Core Viewpoint - The company has signed a technology licensing agreement that allows its subsidiary to utilize approximately 1,780 patents and 110 software copyrights in the Greater China region, which is crucial for its strategic development in humanoid robotics [1] Group 1: Technology Licensing Agreement - The agreement was signed between the company's subsidiary AI Group and its partner, allowing the use of significant intellectual property (IP) related to humanoid robotics [1] - The IP includes exclusive rights to humanoid robot operating systems and cloud brain platforms, as well as non-exclusive rights to smart joint technology and other core hardware technologies [1] Group 2: Strategic Development - The company aims to develop and maintain its own humanoid robots for applications in education, healthcare, elderly care, property management, and other real-life scenarios [1] - This initiative aligns with the company's goal of being at the forefront of technological innovation and seizing emerging market opportunities in the robotics sector [1] Group 3: Importance of IP - The IP obtained through the licensing agreement is essential for the successful implementation of the company's strategic plan [1] - By leveraging this IP, the company intends to accelerate development, enhance the functionality and reliability of humanoid robots, and shorten time-to-market [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，亦明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 Hong Kong Robotics Group Holding Limited 港仔機器人集團控股有限公司 （於百慕達註冊成立之有限公司） （股份代號：370） 持續關連交易 與達闥之技術許可協議 茲提述(a)本公司於二零二五年二月十八日刊發之自願性公佈，內容有關本公司與達闥於二 零二五年二月十四日訂立的合作框架協議；(b)本公司於二零二五年三月五日刊發之自願性 公佈，內容有關本公司之全資附屬公司AI集團與達闥於二零二五年三月五日訂立之合作協 議，內容有關（其中包括）以組建方式成立香港仔機器人作為合資公司，以發展與人形機器 人智能技術及產品有關的業務營運以及擬將達闥及其聯屬公司持有的若干IP許可授予香港 仔機器人於中國的全資附屬公司；及(c)本公司於二零二五年三月二十八日刊發之自願性公 佈，內容有關完成重組香港仔機器人為一間由本公司持有51%及達闥持有49%的合資公司及 有關日期為二零二五年三月五日之上 ...

Group 1 - The Hong Kong stock market saw a strong performance in robotics concept stocks, with notable gains from companies such as 首程控股 (up over 11%) and 德昌电机控股 (up over 6%) [1] - Tesla CEO Elon Musk announced plans for an internal meeting focusing on artificial intelligence, autonomous driving systems, and the production of the Optimus robot [1] - PharmAGRl has signed a letter of intent with Tesla to deploy up to 10,000 Optimus 3+ humanoid robots in its agricultural operations and pharmaceutical production [1] Group 2 - 首程控股 reported a year-to-date increase of 164.56% and a market capitalization of 21.756 billion [2] - 德昌电机控股 experienced a year-to-date increase of 287.95% with a market capitalization of 37.918 billion [2] - 速腾聚创 and 华虹半导体 also showed significant year-to-date increases of 46.97% and 160.05% respectively, with market capitalizations of 21.333 billion and 97.603 billion [2]

Group 1 - The robotics sector in the Hong Kong stock market has seen a significant rally, with notable gains in various companies [1] - Notable stock performances include: - 首程控股 (Shou Cheng Holdings) up by 11.39% - 德昌电机控股 (Dechang Motor Holdings) up by 6.51% - 速腾聚创 (Suteng Juchuang) up by 5.77% - 华虹半导体 (Huahong Semiconductor) up by 5.53% - 地平线机器人-W (Horizon Robotics) up by 4.11% [2] - The year-to-date performance of these stocks shows substantial increases, with some companies like 首程控股 and 德昌电机控股 seeing gains of 164.56% and 287.95% respectively [2] Group 2 - Tesla CEO Elon Musk announced plans to hold internal meetings focusing on artificial intelligence, autonomous driving systems, and the production of the Optimus robot [1] - PharmAGRl has signed a letter of intent with Tesla to deploy up to 10,000 units of the Optimus 3+ humanoid robots in its agricultural operations and pharmaceutical production [1]

Core Insights - The collaboration between 港仔机器人集团 and 美年健康 marks a significant shift in the global health industry, introducing AI-driven health services through a strategic partnership valued at over 800 million yuan [1][5]. Group 1: Partnership Overview - The partnership aims to deploy 20,000 "smart health robot examination centers" over the next three years, transforming health services by making them more accessible and convenient for the public [2][4]. - This initiative will create a vast "human-machine collaborative health service network," allowing individuals to receive health assessments in their workplaces, communities, and factories [2][4]. Group 2: Technological Integration - 港仔机器人的 advanced humanoid robots will integrate over 30 instant detection functions, providing comprehensive health data collection, while 美年健康 will leverage its expertise to analyze this data and offer personalized health plans [3][4]. - The "海睿OS" cloud-based medical brain will enable real-time data processing for millions of users, addressing healthcare disparities by providing high-quality health guidance even in remote areas [3][5]. Group 3: Market Impact - The collaboration combines 美年健康's extensive network of over 500 clinics and a large customer base with 港仔机器人的 cutting-edge technology, creating a differentiated service system in health management [4]. - This partnership is expected to reach 300,000 corporate users and millions of individual users, establishing a new standard for AI in healthcare and showcasing China's capabilities in the global medical AI landscape [5].

Core Viewpoint - The partnership between 港仔机器人 and 美年健康 marks a significant advancement in the integration of AI technology into health management, aiming to create a large-scale health service network utilizing intelligent robots [1] Company Summary - 港仔机器人 experienced a stock price increase of nearly 12% at the close, finishing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The company has successfully delivered 1,000 quadruped robots to 香港通宏护卫, demonstrating its recognized commercial viability in the market [1] Industry Summary - The strategic cooperation agreement signed between 港仔机器人 and 美年健康 is valued at over 800 million RMB, representing a historic breakthrough in the health management sector with the introduction of "AI proactive health protection" [1] - Over the next three years, the partnership plans to deploy 20,000 "smart health robot examination centers," aiming to establish the largest "human-machine collaborative health service network" globally [1]

Group 1 - The core viewpoint of the article highlights the strategic partnership between 港仔机器人 (00370) and 美年健康 (002044.SZ), which is expected to leverage their respective strengths in the health management sector [1] - 港仔机器人 experienced a significant stock price increase, closing up 5.43% at 1.36 HKD, with a trading volume of 25.586 million HKD [1] - The partnership involves a commercial contract valued at over 800 million HKD, marking a historic breakthrough in integrating "embodied intelligent humanoid robots" with medical AI models into the health management field [1] Group 2 - 美年健康 operates over 500 offline branches and has a customer base in the millions, providing a nationwide channel network for the collaboration [1] - 港仔机器人 has successfully delivered 1,000 quadruped robots to Hong Kong Tonghong Security, demonstrating its recognized commercial deployment capabilities [1] - Over the next three years, the two companies plan to deploy 20,000 "smart health robot examination centers," creating the largest "human-machine collaborative health service network" globally [1]

Core Insights - The collaboration between Hong Kong-based Portai Robotics and China's Meinian Health marks a significant shift in the global health industry, introducing AI-driven health management solutions through a strategic partnership valued at over 800 million yuan [1][5]. Group 1: Innovative Health Management - The partnership aims to address traditional health management challenges by deploying 20,000 "smart health robot examination centers" over the next three years, making health services more accessible and proactive for individuals [2][4]. - This initiative will create a "15-minute accessible health examination circle," allowing employees and community members to receive health assessments conveniently [2][4]. Group 2: Technological Integration - The collaboration combines Portai Robotics' advanced humanoid robots with Meinian Health's medical expertise, enabling comprehensive health management from detection to rehabilitation [3][4]. - Portai's humanoid robots feature over 30 instant detection functions and are supported by the "Huirui OS" cloud-based medical brain, which can analyze health data in real-time and provide personalized health recommendations [3][5]. Group 3: Strategic Synergy - The partnership leverages Meinian Health's extensive network of over 500 clinics and a large customer base, enhancing the reach of smart health services [4]. - Portai Robotics' technological capabilities complement Meinian Health's market presence, creating a differentiated service system that benefits both companies and their customers [4][5]. Group 4: Global Impact - This collaboration signifies a milestone in China's export of intelligent medical paradigms, establishing a new standard for global medical AI [5]. - The deployment of 20,000 smart examination centers is expected to reach 300,000 corporate users and millions of individual users, contributing to a significant accumulation of health data and setting a benchmark for future health management solutions [5].

Group 1 - The core viewpoint of the collaboration between 港仔机器人集团 and 美年健康 is the establishment of a strategic partnership to revolutionize the health management industry through the integration of humanoid robots and AI medical models, marking a significant milestone in proactive health services [2][7] - The partnership involves the deployment of 20,000 "smart health robot examination centers" over the next three years, aiming to create the largest "human-machine collaborative health service network" globally, making health assessments more accessible [3][5] - 港仔机器人的 humanoid robots are equipped with over 30 instant detection functions, enabling comprehensive health data collection, while the "海睿OS" cloud medical brain analyzes this data to provide personalized health plans [4][6] Group 2 - The collaboration represents a "super complementary" relationship, leveraging 美年健康's extensive offline network of over 500 clinics and 港仔机器人的 advanced technology to enhance the reach and quality of intelligent health services [5][6] - This partnership is not just a commercial agreement but a significant step in defining a new global standard for medical AI, showcasing China's capability in smart healthcare solutions [6][7] - The initiative is expected to reach 300,000 corporate users and millions of individual users, contributing to the accumulation of health data and establishing a unique competitive advantage in the healthcare sector [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，亦明確表示概不就因本公佈全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 Hong Kong Robotics Group Holding Limited 港仔機器人集團控股有限公司 （於百慕達註冊成立之有限公司） （股份代號：370） 二零二五年九月十日舉行的股東週年大會續會 表決結果 茲提述(i)港仔機器人集團控股有限公司（「本公司」）日期為二零二五年八月四日之股東週年大 會通告（「通告」）；及(ii)通函（「通函」）及本公司日期為二零二五年九月七日之公佈，內容有關 本公司原定於二零二五年九月八日舉行之股東週年大會之惡劣天氣下安排。除另有所指外， 本公佈所用詞彙與通函所界定者具有相同涵義。 本公司董事（「董事」）局（「董事局」）欣然宣佈，於本公司在二零二五年九月十日舉行之股東週 年大會續會（「股東週年大會」）上，所有載於通告之獲提呈決議案（「決議案」）均以點算股數方 式表決正式通過。 於股東週年大會日期，本公司之已發行股份數目為2,091,500,991股，即賦予持有人權利 ...